It also remains to be shown if tolerability and efficacy during longer-term treatment with oral PCSK9 inhibitors are sustained especially in patients on multiple medications with established ASCVD or with multiple co-morbidities at very high risk for ASCVD. This evidence concerns the gene PCSK9 and atherosclerosis.